Scilex Holding Company Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Scilex Holding Company (SCLX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.99 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 9.01M shares, a 3.96% increase year-over-year.
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 8.67M shares, a 84.01% decline year-over-year.
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 54.20M shares, a 11.39% increase year-over-year.
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 48.66M shares.
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 9.08M shares, a 88.51% increase from fiscal 2024.
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 4.82M shares, a 90.00% decline from fiscal 2023.
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 48.17M shares, a 72.38% increase from fiscal 2022.
- Scilex Holding Company antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 27.94M shares, a 47.32% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 8.99M shares 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | 9.01M shares 10-Q · filed 2026-05-20 | |||||||
| 2025-12-31 | 9.08M shares 10-K · filed 2026-04-10 | |||||||
| 2025-09-30 | 8.17M shares 10-Q · filed 2025-11-14 | |||||||
| 2025-06-30 | 8.47M shares 10-Q · filed 2026-08-14 | |||||||
| 2025-03-31 | 8.67M shares 10-Q · filed 2026-05-20 | |||||||
| 2024-12-31 | 4.82M shares 10-K · filed 2026-04-10 | 168.64M shares 10-K · filed 2025-03-31 | ||||||
| 2024-09-30 | 5.47M shares 10-Q · filed 2025-11-14 | 81.05M shares 10-Q · filed 2025-01-17 | ||||||
| 2024-06-30 | 5.29M shares 10-Q · filed 2025-08-13 | 74.71M shares 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | 54.20M shares 10-Q · filed 2024-05-13 | |||||||
| 2023-12-31 | 48.17M shares 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | 46.26M shares 10-Q · filed 2023-11-14 | |||||||
| 2023-03-31 | 48.66M shares 10-Q · filed 2023-08-11 | 48.00M shares 10-Q · filed 2023-05-12 | ||||||
| 2022-12-31 | 27.94M shares 10-K · filed 2024-03-12 | |||||||
| 2021-12-31 | 18.97M shares 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |